Sartorius Stedim Biotech takes majority stake in AllPure Technologies

Published: 29-Apr-2014
Finance

Takeover extends portfolio for single-use bioprocessing


Sartorius Stedim Biotech (SSB), an international supplier to the pharmaceutical and biotech industries, has agreed to take a majority stake in US start-up company AllPure Technologies, based in New Oxford, Pennsylvania.

AllPure, which employs 25 people, has been operating for four years and in 2013 earned revenue of around US$3m. The company specialises in single-use components for biopharmaceutical applications, such as aseptic sampling techniques.

No financial terms have been disclosed.

Reinhard Vogt, a member of SSB’s Executive Board, said: 'AllPure further completes our portfolio with innovative products that help our customers develop and manufacture their pharmaceutical drugs safer and more efficiently.'

Sartorius Stedim Biotech offers integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies to the pharmaceutical and biopharmaceutical industries.

  • Companies:
  • Sartorius
See more

You may also like

Finance

MarkHerz and Polyplus collaborate to advance CGT process standards and lower costs

Read more
Polyplus (part of Sartorius) has inked a collaboration with pioneering Korean cell and gene therapy (CGT) CDMO, MarkHerz, to set new CGT efficiency standards focused on decreasing cost and increasing quality per dose of a therapeutic product

Trending Articles

  1. Small molecules: big market opportunities The rapid rise of biologic drugs in recent years has been accompanied by a market narrative that suggests that innovation and new treatments will be fuelled by breakthroughs in this area, leading to a decline in the small molecule pipeline. This is far from true, notes Kevin Cook, Chief Executive Officer at Sterling Pharma Solutions; both are increasing and small molecule drugs continue to be a mainstay of many drug development portfolios
  2. Policy vacuum risks UK becoming a medicines supply backwater The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
  3. Lonza appoints President of Capsules and Health Ingredients Christian Seufert joins from BASF, where he has worked for the last 20 years. Most recently, he held the role of Senior VP for the Global Business Unit Pharma Solutions
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    The pros and cons of distribution agreements For life sciences companies seeking to break into overseas markets, distribution agreements are central to success
  5. AstraZeneca to stop production of Pulmicort pMDI Agreements with SkyePharma expected to be terminated

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Finance

MarkHerz and Polyplus collaborate to advance CGT process standards and lower costs

Polyplus (part of Sartorius) has inked a collaboration with pioneering Korean cell and gene therapy (CGT) CDMO, MarkHerz, to set new CGT efficiency standards focused on decreasing cost and increasing quality per dose of a therapeutic product
Manufacturing

Sartorius and Repligen combine technologies for integrated bioreactor system

The two companies have incorporated Repligen XCell ATF upstream intensification technology into Sartorius’ Biostat STR bioreactor to simplify upstream process intensification
Manufacturing

Sartorious to acquire plasmid manufacturer Polyplus

Polyplus develops and produces transfection as well as other DNA/RNA delivery reagents and plasmid DNA in high quality and GMP grade
Ingredients

Sartorius makes $500m acquisition of biopharma component manufacturer

The life science group's French subgroup Sartorius Stedim Biotech has agreed to acquired UK-based Albumedix to be part of the Bioprocess Solutions Division
Manufacturing

Sartorius and HOF Sonderanlagenbau partner on freeze-thaw products

“With this partnership, Sartorius continues to strengthen its leading position in the freeze-thaw market,” said Eva Lindskog, Head of Fluid Management Technologies at Sartorius
Finance

Sartorius to open manufacturing facility in Hampshire

With the Havant facility, Sartorius now has five locations in the UK, employing over 900 staff members
Research & Development

RoosterBio partners with Sartorius on scale up protocols

Both companies aim to use the data from this collaboration to provide co-learning and development opportunities to support the growing cell and gene therapy industry
Subscribe now